← Human Trials & Peer-Reviewed Studies
No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial
Plain-language guide to PMID 18625000 (2009): randomized controlled trial study of Teriparatide, osteoporosis and bone density.
Key Facts
- PMID
- 18625000
- Journal
- Clinical endocrinology
- Year
- 2009
- Study type
- Randomized Controlled Trial
- Authors
- Anastasilakis AD et al. (8 authors)
- DOI
- 10.1111/j.1365-2265.2008.03342.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Teriparatide in the context of osteoporosis and bone density, published as a randomized controlled trial.
Objective To evaluate the effect of strontium ranelate (SR) on bone turnover markers in women with established osteoporosis previously treated with teriparatide (TPTD--recombinant human PTH 1-34).
Why It Was Studied
DESIGN PATIENTS: Twenty-two postmenopausal Caucasian women (aged 65.7 +/- 1.7 years) with established osteoporosis previously treated with TPTD 20 microg daily for 18 months were randomly assigned to receive either SR (SR group, n = 11) or calcium and vitamin D (control group, n = 11).
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.
Blood samples for serum N-terminal propeptide of type 1 collagen (P1NP), C-terminal telopeptide of type 1 collagen (CTx) and total alkaline phosphatase (ALP) were obtained from all women before (pre-TPTD) and after (post-TPTD) TPTD administration, as well as 6 months after SR or calcium/vitamin D administration (post-SR/Ca).
How the Study Was Run
The design is described as randomized.
Random assignment meant chance, not the researchers, decided who got Teriparatide and who got the comparison, which limits bias.
What Was Measured
Topics PubMed links to this paper include Alkaline Phosphatase, Bone Density Conservation Agents, Bone and Bones, Calcium, Collagen Type I, Organometallic Compounds and Osteoporosis, Postmenopausal.
What This Means in Plain Language
The paper is a randomized study of Teriparatide in people with osteoporosis and bone density.
The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2009 (Clinical endocrinology), a journal based in England.
More context: the Teriparatide compound page, Osteoporosis and bone density research.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.